sodium cholate | 361-09-1

• 物质功能分类: 有机原料 - 有机金属盐
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: sodium cholate
• 英文别名: cholic acid sodium salt；sodium;(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate
• CAS: 361-09-1
• 化学式: C₂₄H₃₉O₅*Na
• 分子量: 430.56
• InChiKey: NRHMKIHPTBHXPF-TUJRSCDTSA-M

物化性质

• 熔点：
  >225°C (dec.)
• 比旋光度：
  35 º (c=0.6, ethanol)
• 密度：
  0.999 at 20.09℃
• 溶解度：
  可溶于DMSO（轻微）、乙醇（轻微、超声处理）、甲醇（轻微）、水
• LogP：
  4.3 at 22℃ and pH5.7
• 稳定性/保质期：
  胆酸一水合物是一种白色片状结晶。无水物的熔点为198℃。在不同溶剂中的溶解度如下：水中0.28g/L，醇30.56g/L，醚1.22g/L，氯仿5.08g/L，苯0.36g/L，丙酮28.24g/L，冰醋酸152.12g/L，并且它也溶于碱溶液。它的味道先是苦后转为甜，与毛地黄皂苷混合不会产生沉淀。

计算性质

• 辛醇/水分配系数(LogP)：
  -0.88
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  101
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• TSCA：
  Yes
• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  29173990
• RTECS号：
  FZ9600000
• 储存条件：
  棕色玻璃瓶密封包装，在低温下存储。

SDS

Name:	Cholic acid sodium salt 99% (Titr.) Material Safety Data Sheet
Synonym:	Sodium cholate; 3alpha,7alpha,12alpha-Trihydroxy-5-cholanic acid sodium salt; Cholic acid, monosodium salt, sodium cholic acid; Cholan-24-oic acid, 3,7,12-trihydroxy-, monosodium salt, (3-alpha,5-beta,7-alpha; Cholic acid, monosodium salt; D
CAS:	361-09-1

Section 1 - Chemical Product MSDS Name:Cholic acid sodium salt 99% (Titr.) Material Safety Data Sheet
Synonym:Sodium cholate; 3alpha,7alpha,12alpha-Trihydroxy-5-cholanic acid sodium salt; Cholic acid, monosodium salt, sodium cholic acid; Cholan-24-oic acid, 3,7,12-trihydroxy-, monosodium salt, (3-alpha,5-beta,7-alpha; Cholic acid, monosodium salt; D

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
361-09-1	Cholic acid sodium salt	99	206-643-5

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Hygroscopic (absorbs moisture from the air).The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract.
Inhalation:
May cause respiratory tract irritation. May cause effects similar to those described for ingestion.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Get medical aid immediately. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid immediately. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Sweep up, then place into a suitable container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Store protected from moisture.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 361-09-1: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystals
Color: white
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 198 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water: Soluble.
Specific Gravity/Density: Not available.
Molecular Formula: C24H39NaO5
Molecular Weight: 430.55

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, strong oxidants, exposure to moist air or water.
Incompatibilities with Other Materials:
Oxidizing agents, moisture.
Hazardous Decomposition Products:
Acrid smoke and fumes.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 361-09-1: FZ9600000 LD50/LC50:
CAS# 361-09-1: Oral, mouse: LD50 = 2400 mg/kg.
Carcinogenicity:
Cholic acid sodium salt - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 361-09-1: 1
Canada
CAS# 361-09-1 is listed on Canada's DSL List.
CAS# 361-09-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 361-09-1 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

性状 白色或无色粉末，味苦。

用途 胆酸钠可用于生化研究和动物实验中配制高脂饲料。此外，它还可用作消炎药物、阴离子型蛋白去污剂，并且是用于水溶液中的还原剂的一种生物表面活性剂。

化学性质 胆汁酸是一类存在于胆汁中的胆烷酸的总称，为白色粉末，无臭味，苦涩。其碱金属盐，如胆酸钠，易溶于水和醇中。天然的胆汁酸通常以肽键与甘氨酸或牛磺酸结合，并与钠、钾离子形成胆汁酸盐存在于胆汁中。

生产方法

• 方法一：酸沉淀法

  • 胆汁酸粗品制备：
    1. 取牛（或羊、猪）胆汁加热浓缩至半。
    2. 加入1-2倍体积的95%乙醇，回流提取几分钟，得提取液。
    3. 将提取液冷却并过滤，滤液蒸馏回收乙醇至起泡，得浸膏。
    4. 在浸膏中加入稀盐酸调pH值为3-4，放置过夜后倾出上清液，沉淀物即为胆汁酸粗品。

• 方法二：乙醇提取法

  • 胆膏预处理：
    1. 取胆膏并加入其质量的1/10至1/5的活性炭。
    2. 加热，充分搅拌后蒸去水分直至固形物能粉碎，得处理后的胆膏。
  • 胆汁酸盐粗品制备：
    1. 取经预处理的胆膏加95%乙醇提取3-5次，合并滤液。
    2. 将滤液蒸馏回收乙醇，并干燥得到淡黄色的胆汁酸盐粗品。

• 方法三：盐析法

  • 胆汁酸盐粗品制备：
    1. 取胆汁加入乙醇去除蛋白质，残液蒸去乙醇。
    2. 加入100-200g/L氯化钠低温放置几日，析出大部分胆汁酸盐后过滤得到粗品。
  • 胆汁酸盐精品制备：
    1. 取胆汁酸盐粗品用饱和氯化钠水溶液洗涤两次，干燥并粉碎。
    2. 加入95%乙醇加热提取，加活性炭脱色后蒸干得胆汁酸盐精品。

• 方法四：以胆固醇为原料

  • 初级胆汁酸的合成： 胆固醇在多种酶的作用下经过一系列分解代谢形成结合型初级胆汁酸（胆酸和鹅去氧胆酸）。
  • 次级胆汁酸的合成： 初级胆汁酸随胆汁进入小肠参与脂类消化吸收，大部分未经变化被重吸收入门静脉血循环。约1/4的结合型初级胆汁酸在空肠、回肠及结肠上段，在细菌酶催化下进一步生成去氧胆酸和石胆酸次级胆汁酸（过程中也可产生少量熊脱氧胆酸）。
  • 结合型胆汁酸的合成： 肝细胞合成结合型胆汁酸，与甘氨酸或牛磺酸结合后分泌入胆道。

反应信息

• 作为反应物：
  描述：

  sodium cholate 在 Pseudomonas fluorescens B₂₆ broth 作用下， 以 水 为溶剂， 反应 48.0h， 以41%的产率得到去氢胆酸
  参考文献：
  名称：

  Regioselective microbial oxidation of bile acids

  摘要：

  High regioselectivity in the microbial oxidation of C-7, C-3 and C-12 hydroxyl groups of cholic, chenodeoxycholic, deoxycholic and hyocholic acids 1-4 is reported. The tested microrganisms have been isolated from 50 enviromental samples withdrawed from an industry that extracts and purify bile acids. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(97)10408-2
• 作为产物：
  描述：

  胆酸 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 1.0h， 生成 sodium cholate
  参考文献：
  名称：

  胆汁酸的羟基-双膦酸类似物的合成，表征和生物学活性

  摘要：

  现在，双膦酸盐（BPs）是用于与骨吸收增加有关的疾病（例如骨质疏松症和肿瘤性骨病）的最广泛使用的药物。BP的一个显着缺点是口服吸收差，双膦酸盐骨架中胆汁酸取代基的存在会增强它们的口服吸收，而没有毒性作用。提出了含胆汁酸的羟基双膦酸酯的直接合成方法和这些药学上重要分子的完整表征，包括亲和力评估和与羟基磷灰石的结合机理。使用中性红测定法在L929细胞系和破骨细胞的原代培养物中测定了含胆汁酸的双膦酸盐的生物活性。发现新化合物的生物活性优于已确定活性的双膦酸酯。

  DOI：

  10.1016/j.ejmech.2012.03.020
• 作为试剂：
  描述：

  苯甲醛二乙缩醛 在 胆酸 、 水 、 sodium cholate 作用下， 生成 乙醇 、 苯甲醛
  参考文献：
  名称：

  O'Connor, Charmian J.; Wallace, Robert G., Australian Journal of Chemistry, 1984, vol. 37, # 9, p. 1881 - 1893

  摘要：

  DOI：

文献信息

• Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
  申请人：——

  公开号：US20030069170A1

  公开（公告）日：2003-04-10

  Pharmaceutical compositions that include a drug-oligomer conjugate, a fatty acid component, and a bile salt component are described. The drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1. Methods of treating diseases in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.

  描述了包括药物-寡聚物共轭物、脂肪酸成分和胆盐成分的药物组合物。药物以共价键连接到寡聚物基团上。脂肪酸成分和胆盐成分以1:5至5:1的重量比存在。还提供了利用这种药物组合物治疗需要此类治疗的受试者的方法，以及提供这种药物组合物的方法。
• BORON-CONTAINING SMALL MOLECULES
  申请人：Xia Yi

  公开号：US20100256092A1

  公开（公告）日：2010-10-07

  This invention relates to, among other items, 6-substituted benzoxaborole compounds and their use for treating bacterial infections.

  这项发明涉及6-取代苯硼酯化合物等物品，以及它们用于治疗细菌感染的用途。
• [EN] ANALGESIC THAT BINDS FILAMIN A<br/>[FR] ANALGÉSIQUE QUI SE LIE À LA FILAMINE A
  申请人：PAIN THERAPEUTICS INC

  公开号：WO2010051374A1

  公开（公告）日：2010-05-06

  A compound, composition and method are disclosed that can provide analgesia. A contemplated compound has a structure that corresponds to Formula A, wherein A, B, X, R1, R2, R7 and R8, and the dashed lines are defined within.

  公开了一种化合物、组合物及方法，能够提供镇痛效果。所考虑的化合物具有与式A相对应的结构，其中A、B、X、R1、R2、R7和R8以及虚线均在定义范围内。
• [EN] PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT D'ANTIGÈNE MEMBRANAIRE SPÉCIFIQUE À LA PROSTATE
  申请人：AMBRX INC

  公开号：WO2013185117A1

  公开（公告）日：2013-12-12

  This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αPSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αPSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.

  本发明涉及前列腺特异性膜抗原（PSMA）抗体及包含至少一个非天然编码氨基酸的抗体药物偶联物。公开了具有一个或多个非天然编码氨基酸的αPSMA抗体，以及进一步公开了抗体药物偶联物，其中本发明的αPSMA抗体与一个或多个毒素偶联。还公开了非天然氨基酸多拉司汀类似物，这些类似物在翻译后进一步修饰，以及实现这些修饰的方法和纯化这些多拉司汀类似物的方法。通常，修饰的多拉司汀类似物包括至少一个肟、羰基、二羰基和/或羟基胺基团。进一步公开了使用此类非天然氨基酸抗体药物偶联物、多拉司汀类似物和修饰的非天然氨基酸多拉司汀类似物的方法，包括治疗、诊断和其他生物技术用途。
• [EN] 3-ARYLOXY AND 3-HETEROARYLOXY SUBSTITUTED BENZO(B) THIOPHENES AS THERAPEUTIC AGENTS WITH PI3K ACTIVITY<br/>[FR] BENZO[B]THIOPHENES A SUBSTITUTION 3-ARYLOXY ET 3-HETEROARYLOXY EN TANT QU'AGENTS THERAPEUTIQUES A ACTIVITE PI3K
  申请人：WARNER LAMBERT CO

  公开号：WO2004108715A1

  公开（公告）日：2004-12-16

  The present invention provides benzo[b]thiophenes of Formula (I), wherein R1, R2, R3, R4, R5, and L have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cardiovascular diseases, and cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (I).

  本发明提供了式(I)的苯并[b]噻吩，其中R1、R2、R3、R4、R5和L具有规范中为其定义的任何值，以及药用可接受的盐，这些盐作为治疗疾病和状况的药剂是有用的，包括炎性疾病、心血管疾病和癌症。另外还提供了包含一个或多个式(I)化合物的药物组合物。

表征谱图